Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04124198Not ApplicableActive Not Recruiting

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Role: lead

NCT07290946Phase 2Not Yet Recruiting

Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors

Role: lead

NCT03942380Not ApplicableUnknown

Cell-free Tumor DNA in Head and Neck Cancer Patients

Role: lead

NCT03963648Not ApplicableUnknown

NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP

Role: lead

NCT05045846Completed

Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection.

Role: lead

NCT03964324Not ApplicableCompleted

NO Measurements in Screening for Asthma and OSA, in Patients With Severe Snoring

Role: lead

All 6 trials loaded